94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
Nuria Carballo1,2*
Enric Garcia-Alzórriz3Olivia Ferrández1,2María Eugenia Navarrete-Rouco1Xavier Durán-Jordà4Carolina Pérez-García5Jordi Monfort2,5Francesc Cots3Santiago Grau1,2- 1Pharmacy Department, Hospital del Mar – Parc de Salut Mar, Barcelona, Spain
- 2Universitat Autònoma de Barcelona, Barcelona, Spain
- 3Management Control Department, Hospital del Mar – Parc de Salut Mar, Barcelona, Spain
- 4Methodology and Biostatistics Support Unit, Institute Hospital del Mar for Medical Research (IMIM), Barcelona, Spain
- 5Department of Rheumatology, Hospital del Mar – Parc de Salut Mar, Barcelona, Spain
by Carballo, N., Garcia-Alzórriz, E., Ferrández, O., Navarrete-Rouco, M. E., Durán-Jordà, X., Pérez-García, C., Monfort, J., Cots, F., and Grau, S. (2021). Front. Pharmacol. 12:752879. doi: 10.3389/fphar.2021.752879
In the published article, there was an error regarding the affiliations for Nuria Carballo, Olivia Ferrández, Jordi Monfort and Santiago Grau. These authors all have an additional affiliation, listed as “Universitat Autònoma de Barcelona, Barcelona, Spain”.
In addition, there was an error in the Acknowledgements section in the original article. The following statement was should have been included:
“This study is part of a PhD programme in Medicine of the Universitat Autònoma de Barcelona. This study was presented, in part, as a poster at the EULAR Virtual Congress, 2–5 June 2021 in Paris, France.”
The authors apologize for these errors and state that they do not change the scientific conclusions of the article in any way.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: rheumatic disease, biologics, persistence, healthcare resource utilization and costs, anti TNF agents
Citation: Carballo N, Garcia-Alzórriz E, Ferrández O, Navarrete-Rouco ME, Durán-Jordà X, Pérez-García C, Monfort J, Cots F and Grau S (2022) Corrigendum: Impact of Non-Persistence on Healthcare Resource Utilization Costs in Patients With Immune-Mediated Rheumatic Diseases Initiating Subcutaneous TNF-Alpha Inhibitors: A Before-and-After Study. Front. Pharmacol. 13:867017. doi: 10.3389/fphar.2022.867017
Received: 31 January 2022; Accepted: 31 January 2022;
Published: 07 March 2022.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2022 Carballo, Garcia-Alzórriz, Ferrández, Navarrete-Rouco, Durán-Jordà, Pérez-García, Monfort, Cots and Grau. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Nuria Carballo, bmNhcmJhbGxvQHBzbWFyLmNhdA==